BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 13, 2020
View Archived Issues
In AML, collapse prevents relapse
Read More
Notable responses seen in COVID-19 patients with respiratory failure given RLF-100
Read More
Daiichi Sankyo describes new SIRT6 activators
Read More
G protein-coupled receptor 35 modulators discovered at Precision IBD
Read More
Novartis presents NLRP3 inflammasome inhibitors
Read More
Merck KGaA discovers dual adenosine A2A/A2B receptor antagonists
Read More
Discovery and preclinical evaluation of anticancer agent, PVHD-303
Read More
First-in-human data presented for [68Ga]P15-041 radiotracer
Read More
Yumanity Therapeutics identifies stearoyl-CoA desaturase 1/5 inhibitors
Read More
VBL announces second successful pre-planned interim analysis of the phase III OVAL study
Read More
First patient enrolled in phase III InPedILD study of nintedanib
Read More
FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy
Read More
First phase I study of ATG-017 approved in Australia
Read More
Recombinant SARS-CoV-2 S1-Fc fusion protein shows promise in animal species
Read More
Treadwell initiates phase II study of CFI-400945 and durvalumab in TNBC
Read More
TREM2 targeting can synergize with checkpoint blockade
Read More
Phase I study results support further evaluation of yellow fever monoclonal antibody TY-014
Read More
Bio-Path begins dosing in amended stage 2 of phase II prexigebersen study in AML
Read More